Dermatology is evolving rapidly — new treatments, new approvals, and new insights are transforming how we care for skin, hair, and inflammatory conditions. If you’ve wondered what’s “next” in skin health, here are some of the most promising advances in 2025, and how they may impact your treatment plan at Foxhall Dermatology.
In September 2025, the FDA expanded approval of Opzelura cream (a topical JAK inhibitor) for treating atopic dermatitis in children aged 2 to 11 years, now offering a non‑steroidal option for younger patients. Reuters
This opens up safer long‑term management possibilities for pediatric eczema and may reduce reliance on steroids.
Recent studies show clascoterone cream 1%, an androgen receptor blocker, is effective for both inflammatory and non‑inflammatory acne lesions in patients aged 12 and up. MDPI
This adds an option especially helpful for acne patients with hormonal components or sensitive skin, where systemic therapy or stronger topicals are less desirable.
A narrative review of recent studies underscores that personalized strategies—combining lasers, microneedling, PRP, and chemical peels—show the best results for acne scarring. PMC
Also, newer laser modalities are increasingly used as adjuncts or first‑line treatments in certain acne cases. PubMed
Baricitinib, ritlecitinib, and deuruxolitinib have shown strong clinical outcomes in alopecia areata trials, with many patients achieving significant hair regrowth in several months. PubMed+1
Use and safety continue to be refined, especially in patients with other risk factors.
Recent trials show that salicylic acid gels with barrier‑supportive agents can reduce acne lesions, control oil, and improve hydration in sensitive or acne‑prone skin. PMC
Experts increasingly recommend starting early with retinoids and simplifying product regimens to prevent irritation and long‑term scarring. PubMed+1
Whenever new drugs or treatments appear, there are important safety considerations:
JAK inhibitors are powerful but may have infection risk, cardiovascular effects, or other side‑effects. Discuss your overall health and any medications. Dermis+1
For acne/hormonal therapies or anti‑androgens (like clascoterone), monitor for side effects, especially with long‑term use.
At Foxhall Dermatology, our goal is always to balance innovation with safety. Here’s how we may integrate these trends into patient care:
For pediatric eczema: Opzelura may now be an option for younger children who need alternatives to steroids.
For patients with hormonal or acne issues resistant to standard therapy: Clascoterone, combination regimens, lasers, or simpler topical routines could yield better results.
Patients with acne scarring or hair loss: we’ll continue leveraging combinations of PRP, microneedling, laser therapies, and possibly JAK inhibitors (where applicable) to optimize outcomes.
